Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's ... Sacramento Bee Meanwhile, Biogen and partner Abbott (NYSE:ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-weekly subcutaneous injection for relapsing-remitting MS. |
